budget impact of a 10% ready-to-use intravenous immunoglobulin in the treatment of primary immunodeficiency in belgium现成的10%的预算影响静脉注射免疫球蛋白治疗原发性免疫缺陷在比利时.pdfVIP

Vol.1, No.3, 183-187 (2009) Health doi:10.4236/health.2009.13030 Budget impact of a 10% ready-to-use intravenous immunoglobulin in the treatment of primary immunodeficiency in Belgium Steven Simoens Research Centre for Pharmaceutical Care and Pharmaco-economics, Katholieke Universiteit Leuven, Leuven, Belgium; steven.simoens@pharm.kuleuven.be Received 10 July 2009; revised 2 September 2009; accepted 5 September 2009. ABSTRACT often require lifelong therapy [3]. Immunoglobulin the- rapy in PID replaces functionally deficient or absent The aim of this study is to compute the budget immunoglobulins, reduces the incidence of infections, impact of adopting Kiovig, a new ready-to-use and prevents organ damage caused by infections [4]. 10% liquid immunoglobulin preparation, as a Immunoglobulin therapy is administered via the intra- treatment for primary immunodeficiency from muscular, intravenous or subcutaneous route. the perspective of the Belgian health care payer. Kiovig (Baxter International Inc.), a ready-to-use 10% The analysis compared the “world with Kiovig” liquid immunoglobulin preparation, is medically indi- to the “world without Kiovig” and calculated cated for the treatment of, amongst other indications, PID how a change in the mix of immunoglobulins disorders [5]. This plasma-derived product consists of